Actemra (tocilizumab) vs. Prolia (denosumab): *RANKL stimulates osteoclasts, Prolia binds to RANKL *Actemra reduces joint devastation & bone loss *IL-6 and the soluble IL-6 receptor both induce bone loss by inducing RANKL appearance https://t.co/8WWHVy

11-3-2022: China: The anti-osteoporosis drug, Actemra (tocilizumab), was called in to rescue 112 kids. "treatment with methotrexate alone was an independent risk factor for failure" https://t.co/GGwdeYpjpr https://t.co/OoHBNCoZUr https://t.co/8yo3tTUwsP h

10-6-22: Both Actemra (tocilizumab) & Prolia (denosumab) are good osteoporosis drugs that increase bone density & reduce bone fractures. However, Actemra benefits the whole body; Prolia only benefits bone: https://t.co/8WWHVyEfd2 https://t.co/s87

6-19-2022: Actemra (tocilizumab) both prevents cancers and slows down existing cancers: https://t.co/EPDlIn55Cu https://t.co/2ehKDTwBu9 https://t.co/8WWHVym5YU https://t.co/6QCImEYyF1 https://t.co/5cldUzfKIN https://t.co/ly9XIAErqy https://t.co/tk66TwFH9a

6-15-2018: Showdown in Germany between the osteoporosis drug, Actemra (tocilizumab), and TNF-α inhibitors for preventng bone loss in RA patients. Actemra won: https://t.co/6QCImEYyF1 https://t.co/z6Tpo5OgNd https://t.co/8yo3tTCneH https://t.co/GGwdeYGmrr

4-14-2021: In a study just released today from Ludwigshafen, Germany, don't pull your teeth out while receiving Actemra (tocilizumab), Prolia (denosumab), or any bisphosphonate. Actemra is a very beneficial osteoporosis drug: https://t.co/8WWHVym5YU http

4-21-2021: In a study released today from Dhaka, Bangladesh, what caused the sudden, severe muscle damage in this COVID-19 patient? Was it the high-dose corticosteroids or the virus? https://t.co/GGwdeYGmrr https://t.co/RIgFap3i0C https://t.co/9CyXXGmHAd

1-25-2020: In a study just released today from São Paulo, Brazil, Actemra (tocilizumab) reduced the severity of bone density loss: https://t.co/z6Tpo5wFVF https://t.co/8yo3tTTYDh https://t.co/6QCImFga3B https://t.co/GGwdeYoLzT https://t.co/RIgFaoLH94 http

11-17-2020: In a clinical trial just released today from Brest, France, good news for Actemra (tocilizumab) for halting the damage to bone density in 20 polymyalgia rheumatica patients https://t.co/bM4dSaH7de https://t.co/z3XhW7R3I1 https://t.co/GGwdeYGmrr

3-1-2018: The osteoporosis drug, Prolia (denosumab), was combined with Actemra (tocilizumab) or Orencia (abatacept) or TNF-α inhibitors for improving the bone density of rheumatoid arthritis patients. Prolia plus Actemra won: https://t.co/05yazwo6BT http